ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

Aurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

ViiV & MPP extend voluntary licensing long-acting injectable HIV treatment, Indian pharma to benefit: Our Bureau, Bengaluru Tuesday, July 15, 2025, 12:45 Hrs [IST] ViiV Healthcare ...

Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...